Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme

Trial Profile

Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Afatinib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 31 May 2016 Status changed from active, no longer recruiting to completed.
    • 09 Oct 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 15 May 2013 Planned end date changed from 1 Mar 2012 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top